AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable ...

Shares of the company began plunging in November, but its overall strength should set the stock up for some serious potential ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abbott Laboratories (ABT – Research Report), ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in the coming year. After an explosive opening marked by a suite of ...

RALEIGH, N.C. (January 13, 2025) – The first group of apprentices has officially signed on with Amgen in a unique program that will prepare a skilled workforce for the biopharmaceutical leader's ...

The latest trading session saw Amgen (AMGN) ending at $267.10, denoting a -1.14% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 0.12% for the ...

A biotech stock index slid by almost 3%. Amgen is one of those would-be competitors and, at the JPM meeting, executives defended recent trial results for the company’s rival weight loss drug.

Amgen is best known for its success in the biosimilar market. Image credit: Shutterstock / Michael Vi. Amgen has reported that its once-monthly dosing regimen and manufacturing capabilities will be ...